Arti Gupta, Abhishree Geda, Pankaj Kumar Gupta


Aim: Our aim is to determine the diagnostic accuracy of percutaneous fine needle aspiration cytology (FNAC) in various lung carcinoma cases with its histopathological correlation as gold standard.

Material and Method: We performed percutaneous FNAC in sixty patients which are presenting with respiratory symptoms and having localized lung lesions as confirmed radiologically.

Results: In our study, the M: F ratio of 5.67:1 in 78.9% of the lesions, we found primary epithelial lung malignancy, in FNAC finding. Among malignant lesions, twenty two cases were subjected and correlated with histopathological finding and diagnostic accuracy of FNAC is found to be 100% for small cell carcinoma, 87.5% for squamous cell, 83.3% for adenocarcinoma and 66.7% for poorly differentiated large cell carcinoma. The cytological yield of FNAC was 95.0%. Material in three cases was inadequate for interpretation. Adenocarcinoma was the commonest malignancy seen in females. Commonest malignancy seen among smokers was poorly differentiated large cell carcinoma followed by small cell and squamous cell carcinoma and the least common was adenocarcinoma. Sensitivity for diagnosing small cell and non small carcinoma was 100% and 89.5% respectively. Specificity was 100% for each.

Conclusion: Percutaneous transthoracic FNAC is a quite safe, simple and reliable procedure in the diagnosis of lung lesions with a high degree of accuracy, sensitivity and specificity. FNAC should be used frequently to shorten the diagnostic interval and prompt therapy for persistent lung lesions.


Fine needle aspiration Cytology, Primary epithelial Lung malignancy adenocarcinoma, squamous cell carcinoma.

Full Text:



Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137:668–84

Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:5311–20.

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.

Fassina A, Corradin M, Zardo D, Cappellesso R, Corbetti F, Fassan M. Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology. 2011;22:306–12.

Fischer AH, Cibas ES, Howell LP, Kurian EM, Laucirica R, Moriarty AT, et al. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol. 2011;29:3331–2.

Mitul B Modi1*, Mitesh R Rathva1, Nupur R Shah2, Manasi Trivedi1 and Harshad Patel, Role of FNAC in Lung Carcinoma and its Histo-Cytological Correlation, Journal of ISSN: 2376-0060JLPRR ,Lung, Pulmonary & Respiratory Research

- 2016, Volume 3 Issue 4


  • There are currently no refbacks.